March 25 (Reuters) - Mural Oncology PLC MURA.O:
MURAL ONCOLOGY PROVIDES UPDATE ON PHASE 3 ARTISTRY-7 TRIAL OF NEMVALEUKIN IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER
MURAL ONCOLOGY PLC - TOPLINE RESULTS FOR ARTISTRY-6 TRIAL EXPECTED IN Q2 2025
MURAL ONCOLOGY PLC - NEMVALEUKIN HAS FAVORABLE SAFETY PROFILE IN OVER 800 PATIENTS
MURAL- BASED ON OVERALL SURVIVAL DATA OBSERVED IN INTERIM ANALYSIS IN PLATINUM-RESISTANT OVARIAN CANCER, TO NOT PROGRESS TRIAL TO FINAL ANALYSIS
Source text: ID:nGNX6TFw6g
Further company coverage: MURA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.